Madrigal sees ‘tremendous interest’ in NASH drug Rezdiffra

Published on 7 May 2024 on Seeking Alpha

Madrigal Pharmaceuticals (MDGL) reports encouraging initial uptake for its newly approved liver...

Read the rest of the article

Start tracking your investments with Statfolio

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while...

GuruFocus.com · via Yahoo Finance 4 Nov 2024

We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have ...

Insider Monkey · via Yahoo Finance 24 Sep 2024

On May 21, 2024, Robert Waltermire, Senior Vice President and Chief Pharmaceutical Development Of...

GuruFocus.com via Yahoo Finance 24 May 2024

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript May 7, 2024 Madriga...

Insider Monkey via Yahoo Finance 8 May 2024

Madrigal Pharmaceuticals (MDGL) reports encouraging initial uptake for its newly approved liver...

Seeking Alpha 7 May 2024

Rebecca Taub, the President of R&D and Chief Medical Officer at Madrigal Pharmaceuticals, Inc....

Investing.com 6 Apr 2024

Richard Levy, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 11,000 shares of t...

GuruFocus.com via Yahoo Finance 4 Apr 2024

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) director Richard S. Levy has sold a significant port...

Investing.com 4 Apr 2024

James Daly, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 32,489 shares of the...

GuruFocus.com via Yahoo Finance 3 Apr 2024

On Tuesday, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) saw its price target increased by Everco...

Investing.com 20 Mar 2024